LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tyrosine kinase inhibitor (TKI) resistance is a significant challenge in non-small cell lung cancer (NSCLC) treatment.
• FGF3/4/19/CCND1 amplification on chromosome 11q13 is implicated in TKI resistance across various cancers.
• The specific role of these amplifications in NSCLC TKI resistance requires further investigation.

Purpose of the Study:

• To investigate the role of FGF3/4/19/CCND1 amplification in mediating TKI resistance in NSCLC.
• To identify effective therapeutic strategies for overcoming TKI resistance driven by FGF3/4/19/CCND1 amplification.
• To elucidate the underlying molecular mechanisms of resistance and therapeutic response.

Main Methods:

• Generation of FGF3/4/19/CCND1 amplification models in NSCLC cell lines (PC-9, HCC827).
• Assessment of cell proliferation and gefitinib resistance upon FGF3/4/19/CCND1 upregulation.
• Screening of combination inhibitors targeting FGF/FGFR signaling and CCND1/CDK4 complex.
• In vitro and in vivo evaluation of gefitinib combined with LY2874455 and abemaciclib.
• Analysis of MAPK pathway activation by FGFs/CCND1 and its inhibition by combination therapy.

Main Results:

• FGF3/4/19/CCND1 upregulation significantly promoted NSCLC cell proliferation and gefitinib resistance.
• The combination of gefitinib with LY2874455 and abemaciclib demonstrated potent inhibition of resistance both in vitro and in vivo.
• FGFs/CCND1-mediated activation of the MAPK pathway was effectively abolished by the combination therapy.
• The study identified a specific patient subgroup (harboring FGF3/4/19/CCND1 amplification) likely to benefit from this dual-targeting strategy.

Conclusions:

• FGF3/4/19/CCND1 amplification is a key mechanism conferring TKI resistance in NSCLC.
• Dual targeting of FGFR and CCND1/CDK4 with gefitinib, LY2874455, and abemaciclib offers a promising therapeutic approach for resistant NSCLC.
• This study provides a strong rationale for clinical trials evaluating this combination therapy in NSCLC patients with FGF3/4/19/CCND1 amplification.